Načítá se...
Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials
Systemic treatments for advanced hepatocellular carcinoma (HCC) are evolving rapidly and several multi-targeted tyrosine kinase inhibitors have demonstrated a survival advantage over best supportive care. Despite these treatment advances, the majority of HCC patients will progress on tyrosine kinase...
Uloženo v:
| Vydáno v: | Future Oncol |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Future Medicine Ltd
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7444624/ https://ncbi.nlm.nih.gov/pubmed/29663837 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2018-0008 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|